Galectin Therapeutics(GALT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GALT Galectin Therapeutics

Market Closed 04-24 16:00:00 EDT

2.33

-0.04

-1.69%

盘后2.33

+0.000.00%

19:49 EDT

High2.39	Low2.32	Vol180.52K
Open2.36	D1 Closing2.37	Amplitude3.21%
Mkt Cap153.38M	Tradable Cap109.88M	Total Shares65.83M
T/O424.17K	T/O Rate0.38%	Tradable Shares47.16M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GALT","market":"US","secType":"STK","nameCN":"Galectin Therapeutics","latestPrice":2.33,"timestamp":1777060800000,"preClose":2.37,"halted":0,"volume":180524,"hourTrading":{"tag":"盘后","latestPrice":2.33,"preClose":2.33,"latestTime":"19:49 EDT","volume":364,"amount":848.16,"timestamp":1777074575897,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.016877637130801704,"floatShares":47157400,"shares":65827448,"eps":-0.484703,"marketStatus":"Market Closed","change":-0.04,"latestTime":"04-24 16:00:00 EDT","open":2.36,"high":2.3911,"low":2.315,"amount":424172.853332,"amplitude":0.03211,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.484703,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1777276800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1063166400000,"exchange":"NASDAQ","adjPreClose":2.37,"postHourTrading":{"tag":"盘后","latestPrice":2.33,"preClose":2.33,"latestTime":"19:49 EDT","volume":364,"amount":848.16,"timestamp":1777074575897,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5266288517115572,"impliedVol":0.9314,"impliedVolPercentile":0.2271},"requestUrl":"/m/hq/s/GALT/tweets","defaultTab":"tweets","newsList":[{"id":"2624769510","title":"Galectin Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2624769510","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624769510?lang=en_us&edition=fundamental","pubTime":"2026-04-02 00:19","pubTimestamp":1775060375,"startTime":"0","endTime":"0","summary":"Galectin Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryGalectin Therapeutics Inc GALT.OQ reported a quarterly adjusted loss of 8 cents per share for the quarter ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nL8N40K237:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GALT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624344555","title":"Galectin net loss narrows 34.4% to $31M in FY25","url":"https://stock-news.laohu8.com/highlight/detail?id=2624344555","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624344555?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:31","pubTimestamp":1774992700,"startTime":"0","endTime":"0","summary":"Galectin Therapeutics posted a net loss applicable to common stockholders of USD 31 million, narrowing 34.32%.Research and development expenses fell to USD 14 million due to NAVIGATE trial costs rolling off.Belapectin NAVIGATE trial showed a 43.2% lower varices incidence in intent-to-treat patients at 18 months for 2 mg/kg versus placebo, though the composite endpoint missed statistical significance.Management said it plans an FDA meeting in Q2 2026, with new NAVIGATE analyses slated for presentation at EASL 2026.Cash and cash equivalents totaled USD 18 million, with runway projected through April 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news br","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL9z6WfT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GALT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624553718","title":"Galectin Therapeutics Files $200 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2624553718","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624553718?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:20","pubTimestamp":1774992012,"startTime":"0","endTime":"0","summary":"Galectin Therapeutics (GALT) filed a registration statement late Tuesday for the sale of $200 million of securities from time to time.The securities cover common stock, warrants, and rights.Net proceeds will be used for general corporate purposes, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","GALT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624537498","title":"Galectin Therapeutics Inc - May Offer up to $200 Mln of Common Stock, Warrants, and Rights - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624537498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624537498?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:12","pubTimestamp":1774987948,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J1OE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GALT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623535337","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Terns Pharmaceuticals (TERN), Sangamo Therapeutics (SGMO) and Galectin Therapeutics (GALT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623535337","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623535337?lang=en_us&edition=fundamental","pubTime":"2026-03-31 23:40","pubTimestamp":1774971609,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Terns Pharmaceuticals (TERN), Sangamo Therapeutics (SGMO) and Gal...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-terns-pharmaceuticals-tern-sangamo-therapeutics-sgmo-and-galectin-therapeutics-galt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-terns-pharmaceuticals-tern-sangamo-therapeutics-sgmo-and-galectin-therapeutics-galt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","TERN","BK4137","HCSG","SGMO","LU0128526141.USD","BK4139","XBI","LABU","LU0109394709.USD","LU0320765992.SGD","XLV","LU0029874061.USD","BK4581","LU0889565916.HKD","GALT","BK4556","BK4007","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623580934","title":"Galectin Therapeutics Q4 EPS $(0.08) Beats $(0.11) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2623580934","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623580934?lang=en_us&edition=fundamental","pubTime":"2026-03-31 22:19","pubTimestamp":1774966799,"startTime":"0","endTime":"0","summary":"Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 57.89 percent increase over losses of $(0.19) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51570016/galectin-therapeutics-q4-eps-0-08-beats-0-11-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GALT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623360589","title":"Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2623360589","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623360589?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:09","pubTimestamp":1774958996,"startTime":"0","endTime":"0","summary":"Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costsOverviewU.S. biotech's 2025 net loss narrowed as R&D expenses declined after NAVIGATE trial endCompany ended 2025 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL1N40J0HX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GALT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623423586","title":"Galectin Therapeutics FY EPS USD -0.48","url":"https://stock-news.laohu8.com/highlight/detail?id=2623423586","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623423586?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:00","pubTimestamp":1774958408,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nPLX181C11:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GALT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623589547","title":"Galectin Therapeutics Inc - FY2025 Net Loss Applicable to Common Stockholders Was $31.0 Mln, or ($0.48) per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2623589547","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623589547?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:00","pubTimestamp":1774958408,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUA1PPKWY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GALT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623258674","title":"Press Release: Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623258674","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623258674?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:00","pubTimestamp":1774958400,"startTime":"0","endTime":"0","summary":"NORCROSS, Ga., March 31, 2026  -- Galectin Therapeutics, Inc. , the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2025.Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said \"We are at an important juncture for the belapectin development program. During 2025, we made meaningful progress advancing the belapectin program and continuing our analysis of the NAVIGATE dataset in patients with MASH cirrhosis and portal hypertension. We are encouraged by the signals observed, including additional biomarkers from the NAVIGATE dataset, and remain focused on evaluating the data as we engage with regulators, potential partners, and leading experts to determine the optimal path forward for the program.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GALT","BK4232","R","BK4022","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622980815","title":"Top News Today/Canada: Government Records C$5.07 Billion Budget Deficit","url":"https://stock-news.laohu8.com/highlight/detail?id=2622980815","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622980815?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:30","pubTimestamp":1774643400,"startTime":"0","endTime":"0","summary":"Canada recorded a deficit in January similar to the year-ago period, as both tax revenue and government spending declined in the month.Canada had a budget deficit of C$5.07 billion in January, the Department of Finance said Friday in its monthly Fiscal Monitor publication. This is largely in line with the C$5.13 billion deficit posted in January of last year. With just two months left in the 2025-26 fiscal year, Canada's budget deficit sits at C$31.21 billion, an increase of about 16% from the comparable year-ago period.The Liberal government's annual budget plan, issued in November, projected a C$78.3 billion deficit in the current fiscal year. Historically, finance ministry data tends to show sizable deficits in the month of March, or the last month of the fiscal year, due to adjustments to tax receipts.Statistics Canada Estimates Wholesale Trade Rose 2.3% in February. The estimate incorporates wholesale transactions excluding petroleum products, oilseeds and grains. The data agency ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","HQI","BCLI","CYCN","FTHM","IEF","GNE","ANNX","BK4079","BK4161","BK4147","BK4081","INLX","BK4097","BK4585","GALT","BK4120","AQMS","AIRJ","CVV","CFA.SI","BK4130","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622873278","title":"Galectin Therapeutics Inc  expected to post a loss of 10 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622873278","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622873278?lang=en_us&edition=fundamental","pubTime":"2026-03-27 23:07","pubTimestamp":1774624063,"startTime":"0","endTime":"0","summary":"Galectin Therapeutics Inc  expected to post a loss of10cents a share - Earnings Preview Galectin Therapeutics Inc GALT.OQ GALT.O is expected to  show no change in quarterly revenue when it reports  re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F1G0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GALT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620421495","title":"Galectin Therapeutics Strengthens Board of Directors With Appointment of Henry Brem, M.d.","url":"https://stock-news.laohu8.com/highlight/detail?id=2620421495","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620421495?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:00","pubTimestamp":1773748809,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nTUA7HNBWN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GALT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620421509","title":"Galectin Therapeutics appoints Henry Brem to board as independent director","url":"https://stock-news.laohu8.com/highlight/detail?id=2620421509","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620421509?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:51","pubTimestamp":1773748265,"startTime":"0","endTime":"0","summary":"Galectin Therapeutics appointed Henry Brem as an independent director to its board. Brem is the Henry Brem Professor of Neurosurgery at Johns Hopkins University and previously served as Director of the Department of Neurosurgery and Neurosurgeon-in-Chief at The Johns Hopkins Medical Institutions. He is also Co-Director of the Brain Cancer Program at the Sidney Kimmel Comprehensive Cancer Center.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely responsible for the information contained th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL81Zr69:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GALT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618946695","title":"Compelling Risk‑Reward in Galectin Therapeutics: Belapectin’s Differentiated Profile and Biomarker Data Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2618946695","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618946695?lang=en_us&edition=fundamental","pubTime":"2026-03-11 18:35","pubTimestamp":1773225330,"startTime":"0","endTime":"0","summary":"Analyst Matthew Keller of H.C. Wainwright reiterated a Buy rating on Galectin Therapeutics, retaining the price target of $11.00. Matthew Keller ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/compelling-risk‑reward-in-galectin-therapeutics-belapectins-differentiated-profile-and-biomarker-data-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/compelling-risk‑reward-in-galectin-therapeutics-belapectins-differentiated-profile-and-biomarker-data-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GALT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614307665","title":"Galectin Therapeutics to Host Virtual KOL Event on Belapectin Development Program for MASH Cirrhosis and Portal Hypertension","url":"https://stock-news.laohu8.com/highlight/detail?id=2614307665","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614307665?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:07","pubTimestamp":1772140048,"startTime":"0","endTime":"0","summary":"Galectin Therapeutics to Host Virtual KOL Event on Belapectin Development Program for MASH Cirrhosis and Portal Hypertension               Galectin Therapeutics Inc. will host a virtual key opinion le","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL37TP4K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014005.SGD","LU0314104364.USD","SG9999014039.USD","BK4585","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014021.USD","LU2210149790.SGD","IE00BKPKM429.USD","BK4112","NDAQ","SG9999014013.SGD","LU2210150020.SGD","BK4139","IE00B64PRP62.GBP","BK4588","GALT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613295735","title":"Galectin Therapeutics Halts Key NASH Cirrhosis Trial, Resetting Expectations for GALT","url":"https://stock-news.laohu8.com/highlight/detail?id=2613295735","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613295735?lang=en_us&edition=fundamental","pubTime":"2026-02-21 00:30","pubTimestamp":1771605038,"startTime":"0","endTime":"0","summary":"Galectin Therapeutics (GALT) ($GALT) announced an update on their ongoing clinical study. Galectin Therapeutics Inc. (GALT) has terminated its seam...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/galectin-therapeutics-halts-key-nash-cirrhosis-trial-resetting-expectations-for-galt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/galectin-therapeutics-halts-key-nash-cirrhosis-trial-resetting-expectations-for-galt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GALT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610666088","title":"Director Kary Eldred Acquires Common Shares of Galectin Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2610666088","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610666088?lang=en_us&edition=fundamental","pubTime":"2026-02-10 05:25","pubTimestamp":1770672358,"startTime":"0","endTime":"0","summary":"Kary Eldred, a director of Galectin Therapeutics Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL9WgrSx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Kary Eldred Acquires Common Shares of Galectin Therapeutics Inc","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GALT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605439539","title":"Galectin Therapeutics Approves Retention Bonuses for Key Executives","url":"https://stock-news.laohu8.com/highlight/detail?id=2605439539","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605439539?lang=en_us&edition=fundamental","pubTime":"2026-01-22 06:29","pubTimestamp":1769034567,"startTime":"0","endTime":"0","summary":"An update from Galectin Therapeutics ( ($GALT) ) is now available. On January 16, 2026, Galectin Therapeutics’ board of directors, acting on the re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/galectin-therapeutics-approves-retention-bonuses-for-key-executives?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/galectin-therapeutics-approves-retention-bonuses-for-key-executives?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GALT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605042435","title":"Galectin Therapeutics Awards Retention Bonuses to Chief Medical and Financial Officers","url":"https://stock-news.laohu8.com/highlight/detail?id=2605042435","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605042435?lang=en_us&edition=fundamental","pubTime":"2026-01-22 06:01","pubTimestamp":1769032911,"startTime":"0","endTime":"0","summary":"Galectin Therapeutics Inc. has approved cash retention bonuses for two of its top executives. Chief Medical Officer Dr. Khurram Jamil will receive a $300,000 bonus, while Chief Financial Officer Jack Callicutt will receive $150,000. Each bonus will be paid in three equal installments on June 1, September 1, and December 1, 2026. The bonuses must be repaid if the officers resign without good reason or are terminated for cause before December 31, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 21, 2026, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL2YQLLf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GALT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.galectintherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.049},{"period":"1month","weight":-0.2048},{"period":"3month","weight":-0.2961},{"period":"6month","weight":-0.5545},{"period":"1year","weight":0.6408},{"period":"ytd","weight":-0.4399}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.087},{"period":"3month","weight":0.0359},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.3059},{"period":"ytd","weight":0.047}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.068623},{"month":2,"riseRate":0.714286,"avgChangeRate":0.183696},{"month":3,"riseRate":0.428571,"avgChangeRate":0.008257},{"month":4,"riseRate":0.4,"avgChangeRate":0.074367},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.039749},{"month":6,"riseRate":0.642857,"avgChangeRate":0.041561},{"month":7,"riseRate":0.5,"avgChangeRate":0.060871},{"month":8,"riseRate":0.642857,"avgChangeRate":0.060015},{"month":9,"riseRate":0.571429,"avgChangeRate":0.009696},{"month":10,"riseRate":0.5,"avgChangeRate":-0.023176},{"month":11,"riseRate":0.357143,"avgChangeRate":-0.053714},{"month":12,"riseRate":0.214286,"avgChangeRate":-0.11026}],"exchange":"NASDAQ","name":"Galectin Therapeutics","nameEN":"Galectin Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Galectin Therapeutics(GALT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Galectin Therapeutics(GALT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Galectin Therapeutics,GALT,Galectin Therapeutics股票,Galectin Therapeutics股票老虎,Galectin Therapeutics股票老虎国际,Galectin Therapeutics行情,Galectin Therapeutics股票行情,Galectin Therapeutics股价,Galectin Therapeutics股市,Galectin Therapeutics股票价格,Galectin Therapeutics股票交易,Galectin Therapeutics股票购买,Galectin Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Galectin Therapeutics(GALT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Galectin Therapeutics(GALT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction